natgillin/translations-raw huggingface dataset:
The therapeutic hosiery item according to claim 1, characterized in that said further yarn (1b) that composes said first rows of knitting (1) is constituted by a yam made of polyamide fibers or natural fibers. 
Terapeutska čarapa prema zahtjevu 1, naznačena time, da se spomenuti daljnji konac (1b), koji tvori neparne redove pletiva (1), sastoji od konca izrađenog od poliamidnih vlakana ili prirodnih vlakana.
In some embodiments, each n is 0 or 1. 
je dušik i R' je odsutan; i svaki n je 0 ili 1.
wherein the at least one user marking area is detected by the device based, at least in part, on: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što kamera sadrži najmanje jednu leću.
The residue was triturated using pet-ether (30-40 °C) and the organic solution concentrated once more to yield (after drying in vacuo.) (+)-B-DHTBZ (6.6 g, ORD +107.8°). 
Ostatak se triturira uporabom petrolej etera (30-40 *C) i organska otopina se koncentrira još jednom dajući (nakon sušenja in vacuo) (+)-B-DHTBZ (6.6 g, ORD +107.8").
A is pyridylene or phenylene, each of which is optionally substituted with one or two groups independently selected from halogen, C1-4-alkoxy, halo-C1-4-alkoxy, C1-4-alkyl, and halo-C1-4-alkyl; 
-A je: pri čemu piridilen je opcijski supstituiran sa jednom ili dvije grupe koje su nezavisno izabrane od halogena, C1-4-alkoksi, halo-C1-4-alkoksi, C1-4-alkil, i halo-C1-4-alkil, i R4 je -CO2R5 ili -C(O)NR5R6;
The uracil compound or the salt thereof according to claim 1 or 2, wherein n represents 1 or 3; 
Spoj uracila ili njegova sol u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da n predstavlja 1 ili 3;
The pharmaceutical compositions formed by combining the novel compounds of the formula (I) and the pharmaceutical acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. 
Farmaceutske smjese nastale kombinacijom novih spojeva formule (1) i farmaceutski prihvatljivih nositelja potom se primjenjuju u raznim oblicima doziranja prikladnim za opisane načine primjene.
The residue was chromatographed on silica (t.l.c. grade Merck Kieselgel 60H, [Trade Mark] 30 g] eluting with dichloromethane plus 0-5% methanol. Appropriate fractions were combined and evaporated. 
Ostatak se kromalografira na silicij-dioksidu (T.L.C. kvaliteta Merck "Kieselgel" 60H, (Trgovačko ime 30 g) eluiranjem s HR P930370_B1 B1 diklorometanom plus 0-5% metanola.
and the wavy line indicates a point of bonding to a ribosyl, deoxyribosyl, or dideoxyribosyl moiety or an analog thereof, wherein the ribosyl, deoxyribosyl, or dideoxyribosyl moiety or analog thereof is in free form, bound to a mono-phosphate, diphosphate, or triphosphate group, optionally comprising an a-thiotriphosphate, B-thiotriphosphate, or Y-thiotriphosphate group, or is included in an RNA or a DNA or in an RNA analog or a DNA analog. 
i valovita linija označava točku vezanja za ribozilnu, deoksiribozilnu ili dideoksiribozilnu skupinu ili njen analog, pri čemu je ribozilni, deoksiribozilni ili dideoksiribozilni ostatak ili njegov analog u slobodnom obliku, vezan za monofosfatnu, difosfatnu ili trifosfatnu skupinu, koja opcijski sadrži a-tiotrifosfatnu, B-tiotrifosfatnu ili Y-tiotrifosfatnu skupinu ili je uključen u RNA ili DNA ili u analog RNA ili analog DNA.
The composition for use according to claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is provided in a subject with a newly diagnosed acute myeloid leukemia (AML), to maintain remission, or in a relapsed or refractory acute myeloid leukemia (AML) subject. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje subjektu s novodijagnosticiranom akutnom mijeloičnom Ieukemijom (AML), da bi se održala remisija ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
The water vehicle of claim 1, wherein the gondola further comprises transparent passenger seating to accommodate a group of passengers among the plurality of passengers. A method comprising: 
Plovilo iz zahtjeva 1, naznačeno time da gondolu (102) nadalje čine transparentna putnička sjedala (324) namijenjena primanju skupine putnika iz pluraliteta putnika.
centrifuging the precipitated supernatant to receive a pellet; 
-centrifugiranja istaloženog supernatanta kako bi se dobio pelet;
it has an improved homogeneity, which is an improved glycosylation homogeneity compared to at least one protein molecule composition of the same protein molecule when expressed in the cell line ATCC No. 
- ima poboljšanu homogenost, koja je poboljšana homogenost glikoziliranja u usporedbi s pripravkom s najmanje jednom molekulom proteina za istu molekulu proteina kada se eksprimira u staničnoj liniji ATCC No.
A compound of Formula (I): and pharmaceutically acceptable salts, solvates, solvates of salts, thereof, wherein: 
L £ 2 (1) i njegove farmaceutski prihvatljive soli, solvati ili solvati soli, naznačen time da:
A process for the preparation of a compound of formula III as defined in Claim 5, which process comprises reaction of a compound of formula IV, in which L2 represents: 
10. Postupak za dobivanje spoja formule III kao što je definirano u zahtjevu 5, naznačen time da postupak sadrži reakciju spoja formule IV,
The fuel feeder of any of claims 1 to 2, wherein the secondary nozzles are: rotatable so that the angle at which the liquid or particulate fuel is directed can be changed; or configured to feed into the gas distribution nozzles; or located proximate the top end of the sloped chute; or configured to be fed separately by a volatile liquid source and by a water source; or configured to be fed separately by a volatile liquid source and by a water source, and are also tied to a fuel moisture sensor; or arranged in a staggered pattern relative to the gas distribution nozzles. An apparatus comprising: 
Dovod goriva prema bilo kojem od zahtjeva 1 do 2, naznačen time što su sekundarne mlaznice: rotirajuće tako da se može mijenjati kut pod kojim se usmjerava tekućina ili gorivo u obliku čestica; ili su konfigurirane za dovođenje u mlaznice za distribuciju plina; ili su smještene u neposrednoj blizini gornjeg kraja nagnutog kanala; ili su konfigurirane da se odvojeno napajaju hlapljivim izvorom tekućine 1 iz izvora vode; ili su konfigurirane da se odvojeno napajaju hlapljivim izvorom tekućine, te su također vezane za osjetnik vlažnosti goriva; ili su postavljene u raspoređenom uzorku u odnosu na mlaznice za distribuciju plina.
A compound of general formula (I) wherein: 
PATENTNI ZAHTJEVI 1. Spoj opće formule (I)
After cooling to room temperature, 2-fluoro-3-trifluoromethylbenzyl bromide (0.22 g, 0.86 mmol) was added, and reflux was resumed for 16 hours. 
Nakon hlađenja na sobnu temperaturu doda se 2-fluor-3-trifluormetilbenzil-bromid (0,22 g, 0,86 mmol), te daljnje refluksira 16 sati.
The enteric coat was applied by spraying of an aqueous suspension of the coat ingredients in a coater, using parameters for the coating process as recommended by the manufacturers of the coating polymers (any suitable coater could be used). 
Enterička ovojnica se nanese sprejanjem vodene suspenzije sastojaka ovojnice u oblagaču, upotrebom parametara za postupak oblaganja prema preporuci proizvođača polimera za oblaganje (može se upotrijebiti bilo koji prikladni oblagač).
Preferred isomers are the dextrorotatory (+) isomers. 
Izomeri za uporabu u skladu s prikazanim izumom su desno-zakrećući (+) izomeri.
Set inlet temperature (°C) 
Temperatura ("C) u
a first binding domain specifically binding to human CD3, and 
(a) prvu vežuću domenu koja se specifično veže na ljudski CD3, i
Said increased diversity index difference is at least 0.02, preferably 0.04, more preferably 0.06 and even more preferably 0.08, when the Simpson's index of diversity is used. 
Smjesa za uporabu prema zahtjevu 1, gdje je ta povećana razlika indeksa raznolikosti barem 0.04, poželjno 0.06 1 još poželjnije 0.08, kada se koristi Simpson indeks raznolikosti.
% to 80 %, such as 20 % to 70 %, such as 20 % to 60 %, such as 30 % to 60 %, such as 35 % to 60 %, such as 35 % to 55 %, such as 40 % to 55 %, such as 40 % to 50 %, such as 44 % to 55 %, such as 42 % to 48 %, by weight of one or more fumaric acid esters selected from di-(C1-C5)alkylesters of fumaric acid and mono-(C1-C5)alkylesters of fumaric acid, or a pharmaceutically acceptable salt thereof, as an active substance; and 
Farmaceutska formulacija u obliku tablete erozijskog matriksa, naznačena time, da obuhvaća: i) kao aktivnu tvar jedan ili više estera fumarne kiseline odabranih od di-(C,-Cs)alkilestera fumarne kiseline 1 mono-(C,-Cs)alkilestera fumarne kiseline od 10% do 80% po masi, ili farmaceutski prihvatljivu sol od istih; 1i) jedan ili više sredstava za kontrolu učestalosti od 1 do 50% po masi; i enteričku oblogu, pri čemu se ta enterička obloga nanosi na razini od 1,5 do 3,5% po masi jezgre, gdje erozija od spomenutog erozijskog matriksa dopušta kontrolirano ili potpomognuto oslobađanje spomenute aktivne tvari.
one or more compounds having the formula: wherein Z is phenyl substituted with from 1 to 5 halogens chosen from fluorine and chlorine; 
djelotvornu količinu spoja s formulom: [image], gdje je Z fenil, supstituiran s od 1 do 5 halogena, koje se bira između fluora i klora;
The capsule according to any of the preceding claims, wherein the perforation means has the general shape of a contoured plate, and wherein the valve means are arrange at the periphery of the plate. 
Kapsula u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što sredstvo za probijanje (5) ima opći oblik hrapave ploče, te što ventil (15) se nalazi na rubu te ploče.
optionally, determining at least one of the ratios of concentrations selected from the group consisting of SEQ ID NO: 10/SEQ ID NO: 4, and SEQ ID NO: 7/SEQ ID NO: 4; and 
kvantificiranju najmanje jednog bakterijskog 16S rDNA slijeda, kojeg se bira iz spiska kojeg čine SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 i SEQ ID NO:10 iz uzorka izmeta iz navedenog subjekta;
The combination comprising wire and elastic thread achieves a certain flexibility due to the elasticity of the textile filament. 
Ova kombinacija koja sadržava žice i elastičnu pređu postiže stanovitu fleksibilnost zbog elastičnosti tekstilnih niti.
injecting the ethanol sample into the alcohol dehydration chamber; 
- < injektiranje uzorka etanola u komoru za dehidraciju alkohola;
A third example is the radio communication apparatus according to the first example, wherein the hopping pattern calculation section calculates the ZC sequence number by hopping the ZC sequence number used outside a CoMP set grouping the plurality of cells for performing transmission and reception in a coordinated manner, when the radio communication apparatus is set as the CoMP terminal by the CoMP mode setting section. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 1, naznačen time da je sekcija izračuna obrasca skoka (104) prilagođena za izračunavanje broja sekvence ZC koristeći prvi obrazac skoka skakajući broj ZC sekvence korišten izvan CoMP seta okupljajući pluralitet ćelija za obavljanje prijenosa i prijema na koordiniran način, kad je radio komunikacijski terminalni uređaj postavljen u CoMP način rada od strane sekcije za postavljanje načina rada CoMP.
Example 6 was repeated with the exception that the 4491 g of microcrystalline cellulose and 1714 g of lactose monohydrate were replaced by 4491 g of lactose monohydrate and 1714 g of microcrystalline cellulose. 
Primjer 6 je ponovljen s razlikom da je 4491 g mikrokristalne celuloze i 1714 g monohidratne laktoze zamijenjeno sa 4491 g monohidratne laktoze i 1714 g mikrokristalne celuloze.
is selected from the group consisting of hydrogen, halo, oxo, and methyl; 
R3 je odabran iz skupine koja sadrži vodik, halo, okso i metil;
When a compound of the invention contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the invention with a chemical equivalent of an acid such as a pharmaceutically acceptable acid. 
Kad spoj izuma sadrži slobodne baze, takve soli se pripravljaju na konvencionalni način tretiranjem otopine ili suspenzije slobodne baze izuma s kemijskim ekvivalentom jedne kiseline kao stoje to farmaceutski prihvatljiva kiselina.
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000, 
(po težini) polietilen oksida koji sadrži, bazirano na reološkim mjerenjima, približnu molekulsku težinu od barem
wherein an edge (13 a) of the top sheet (10) with the adhesive is oriented closest to the spine (2) is adhesive-free. The binding folder according to claim 1, 
Fascikl u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je prednja korica (10) pričvršćena na fascikl (1) uz pomoć ljepila, dodanog na prednjoj korici (10).
wherein Ring A, Ring B and Y are as defined in claim 1, and R<13a> is a bromine atom or an iodine atom, with a boronic acid compound of formula X: 
gdje su Prsten A, Prsten B i Y definirani kao u patentnom zahtjevu 1, a R'* je atom broma ili atom joda, sa spojem boronske kiseline formule X:
The boat of claim 1, wherein the door is configured to pivot inwards and towards a centerline of the boat when the door is moved from the closed configuration to at least a first open position. 
okretanja prema unutra i prema središnjoj liniji trupa broda kada je sklop terase linice ugrađen u brod i vrata (210) premještena iz zatvorene konfiguracije u barem prvi otvoreni položaj i
means (742-0) for encoding service data included in one or multiple Physical Layer Pipes, PLPs, by a Low Density Parity Check, LDPC, scheme; 
sredstvo (702-0) za kodiranje servisnog podatka koji ima najmanje jedno zaglavlje osnovnog frekvencijskog pojasa pomoću sheme kodiranja provjerom pariteta niske gustoće, LDPC;
Titration analysis using a range of protein concentrations determined the optimal protein concentration to be 15 ug per well final concentration. 
Titracijskom analizom pomoću niza koncentracija proteina određeno je da je optimalna koncentracija proteina 15 ug po jažici kao konačna koncentracija.
Composition as defined in claims 2 to 7 for use as a medicament. Composition comprising at least 2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and (2E)-3,7-dimethylocta-2,6-dien-1-ol in a pharmaceutically effective concentration for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-envelopped viruses, RNA enveloped viruses, RNA non-enveloped viruses. 
Sastav koji se sastoji od (-)-Karvona i (+)-Karvona i Trans-Geraniola i barem još jedne komponente izabrane od Eugenol metiletera i Linalooloksida i (cis+trans)-1,2-(+)-Limonen oksida i Lavendulola u farmaceutski učinkovitoj koncentraciji za upotrebu u liječenju i prevenciji bolesti uzrokovanih virusima obavijenim sa DNK, virusima neobavijenim sa DNK, virusima obavijenim sa RNK, virusima neobavijenim sa DNK, koje bolesti su odabrane iz skupine koja se sastoji od:
compounds or salts thereof from the group described by the general formula (V): in which 
spojeve 1li njihove soli 12 skupine opisane općom formulom (V):
Thus Step B of the above-mentioned method is preferably carried out with EDC x HCl as coupling agent (without HOBT) in THF / NMP solvent mixtures having a ratio of 10: 1 to 1:1. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu se korak 8 izvodi s EDC x HCI kao reagensom povezivanja u smjesi otapala THF/NMP.
The metal layer may be polished or grinded. 
Metalni sloj može biti poliran ili brušen.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-iljamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
The term “mammal” is taken to mean any of various warm-blooded vertebrate animals of the class Mammalia, most preferably humans, characterized by a covering of hair on the skin and, in the female, milk-producing mammary glands for nourishing the young. 
Termin "sisavac" uzima se sa značenjem bilo kojeg od različitih toplokrvnih kralježnjaka iz razreda Mammalia (sisavci), najpoželjnije ljudi, za koje je karakterističan pokrov od dlake na koži, a kod ženki i mliječne žlijezde kao izvor mlijeka za ishranu mladunčadi.
The exosome of item 15, wherein the HLA antigen is HLA-A2. 
Egzosom u skladu s patentnim zahtjevom 14, naznačen time što je HLA antigen HLA-A2.
In another preferred embodiment, the invention provides derivatives of Formula (Ia) wherein R13 is selected from H, linear or branched C1-C6 alkyl and R14 is a heterocyclic or heterocycloalkyl group selected from the group consisting of: 1,3-dioxolane, 2,2-dimethyl-1,3-dioxolane, thiophene, 1-methyl-1-morpholino-4-ylethyl, pyrimidine, pyridine, said pyridine optionally substituted with a hydroxy or C1-C6 alkoxy group; pyridinyl-linear or branched C1-C4 alkyl; piperidine, said piperidine optionally substituted with phenyl-C1-C4 alkyl; furane, tetrahydrofurane; 2-tetrahydrofuran-2-ylethyl, pyrrolidine N-carboxylic acid, C1-C4 linear or branched N-alkoxycarbonylpyrrolidin-2-yl; tetrahydropyrane. 
Spoj prema zahtjevu 1, naznačen time da R5 je odabran od H, ravnog ili razgranatog Ci-Cg4 alkila i R,4 je heterociklička ili heterocikloalkilna skupina odabrana iz skupine koju čine: 1,3-dioksolan, 2,2-dimetil-1,3-dioksolan, tiofen, 1-metil-1-morfolino-4-iletil, pirimidin, piridin, navedeni piridin je proizvoljno supstituiran sa HR P20110874 TI hidroksi ili C;-C4 alkoksi skupinom; piridinil-ravni ili razgranati C;-C4 alkil; piperidin, navedeni piperidin proizvoljno supstituiran sa fenil-C,-C, alkilom; furan, tetrahidrofuran; 2-tetrahidrofuran-2-iletil, pirolidin N-karboksilna kiselina, C,-C, ravni ili razgranati N-alkoksikarbonilpirolidin-2-il; tetrahidopiran.
A method according to claim 10, wherein the primary air flow is generally lateral and the further air flow is generally upwards. 
Postupak sukladno patentnom zahjtevu 10, pri čemu je primarni protok zraka generalno bočni 1 daljnji je protok zraka generanalno okomiti.
at least one solubilizing/ emulsifying agent in a quantity between 0% and 70% by weight of the formulation, 
- najmanje jedno sredstvo zasolubiliziranje odnosno emulgiranje, u količini između 0 % i 70 %, težinski, formulacije,
An isolated nucleic acid sequence that encodes the antibody or antigen-binding fragment according to claims 1 to 6. 
Izolirana sekvenca nukleinske kiseline naznačena time da kodira protutijelo ili fragment koji veže antigen prema zahtjevima 1 do 6.
said coloured element (2, 12) is formed by a first portion, which forms said marking (2', 12') printed with a conventional ink, and by a second portion (2", 12") printed with a thermochromic ink; 
(a) navedeni obojani element (2, 12) se formira pomoću prvog odsječka koji oblikuje navedenu oznaku (2', 12) tiskanu s uobičajenom tintom, i pomoću drugog odsječka (2", 12") koji je tiskan termokromnom tintom;
The aqueous suspension according to claim 1, wherein the cation of the at least one water-soluble salt is sodium. The aqueous suspension according to claim 1, wherein the anion of the at least one water-soluble salt is selected from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, oxalate, silicate, hydrates thereof, and any mixture thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da je anion navedene kiseline topive u vodi odabran iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, oksalat, silikat, njihove mješavine i njihove hidrate, poželjnije iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, njihove mješavine i njihove hidrate, te najpoželjnije iz skupine koja sadrži dihidrogen fosfat, monohidrogen fosfat, njihove mješavine 1 njihove hidrate.
Compounds which specifically inhibit glycogen phosphorylase should reduce blood glucose levels in the post-absorptive state; thereby providing adjunctive therapy for Type II (2) Diabetes. 
Spojevi koji specifično inhibiraju glikogen-fosforilazu trebali bi smanjiti razinu glukoze u krvi u postapsorpcijskom stanju; pri čemu osiguravaju dodatnu terapiju za dijabetes tipa II.
a light chain variable region, wherein the CDRL1 comprises the amino acid sequence of SEQ ID NO:15, the CDRL2 comprises the amino acid sequence of SEQ ID NO:27, the CDRL3 comprises the amino acid sequence of SEQ ID NO:35, and a heavy chain variable region wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO:47, the CDRH2 comprises the amino acid sequence of SEQ ID NO:61, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:91; 
Izolirano anti-IL-6 antitijelo koje sadrži: aminokiselinsku sekvencu varijabilne regije lakog lanca označenu Identifikacijskim brojem sekvence (SEQ ID NO): 101 i aminokiselinsku sekvencu varijabilne regije teškog lanca označenu kao SEQ ID NO: 103;
Use according to one of claims 1 to 3, wherein the compound of formula I a or its pharmaceutically acceptable salt is such that R3 represents heteroaryl-(C1-C4)alkyl. 
Uporaba prema jednom od zahtjeva 1 do 3, naznačena time, da je spoj formule Ia ili njegova farmaceutski prihvatljiva sol takav/takva da R> predstavlja heteroaril-(C,-Cx)alkil.
The peptide according to claim 1, wherein said peptide is capable of stimulating CD8 or CD4 T cells. 
Peptid u sklad s patentnim zahtjevom 1, pri čemu navedeni peptid može stimulirati CD8 ili CD4 stanica.
A device according to claim 4, said means for venting consisting of a venting port (7) functioning as a stop flow valve. 
Mikrofluidički uređaj u skladu s patentnim zahtjevom 4, naznačen time što navedeni dio za odzračivanje se sastoji od otvora za odzračivanje (7), koji djeluje kao kao ventil za zatvaranje protoka.
in which each R15 is H or C1-C6 alkyl or the two groups OR15 form, together with the boron atom to which they are attached, a pinacolato boronate ester group, in the presence of a Pd catalyst. 
B(OR') pri čemu svaki R'* predstavlja H ili C,-Ce alkil ili dvije skupine OR'> tvore, zajedno s atomom bora na koji su spojene, skupinu ester pinakolat-boronat, u prisutnosti Pd katalizatora.
The syringe of claim 14, wherein the needle is ½ inch to 5/8 of an inch in length and has a gauge of about 25 to about 31. 
Å trcaljka u skladu s patentnim zahtjevom 14, naznačena time što je igla duga 1,27 em (1/2 inča) do 1,59 em (5/8 inča), te ima kalibar od otprilike 25 do otprilike 31.
The compound for use of claim 1, wherein the disease or disorder is breast cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je genitalno-urinarni Tak.
A compound according to claim 1, wherein R7' is H and R7 is n-ethyl, cyclopropylmethyl, cyclopropyl, cyclobutylmethyl cyclobutyl or mercaptomethyl, preferably n-propyl or 2,2-difluoroethyl. 
Spoj u skladu sa zahtjevom 1, naznačen time, da R7' je H i R7 je n-etil, ciklopropilmetil, ciklobutilmetil ili merkaptometil, povoljno je n-propil ili 2,2-difluoroetil.
The floor panel of claim 10, wherein the press-on portion includes one or more of the following features: 
Podni panel sukladno zahtjevu 4 ili 13, naznačen time što dio na pritisak (15) iskazuje jednu 1li više sljedećih karakteristika:
The pharmaceutical composition according to claim 19, wherein said inflammatory disorder is selected from the group consisting of atherosclerosis, inflammation of the eye including uveitis, iritis, iridocyclitis, alcoholic hepatitis, allograft transplantation, xenograft transplantation, glomerulonephritis, reperfusion injury and acute inflammatory conditions following myocardial infarction and stroke. 
Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena upalna bolest odabrana 12 grupe koja se sastoji od ateroskleroze, upale oka uključujući uveitis, iritis, iridociklitis, alkoholnog hepatitisa, transplantacije alografta, transplantacije ksenografta, glomerulonefritisa, reperfuzijske ozljede 1 akutnih upalnih stanja nakon infarkta miokarda i moždanog udara.